News

Approximately 10% of US patients report having an allergic relation to penicillin, yet only 1% of the population are truly allergic.

Cristen Whittaker, PharmD, explains the findings of an analysis that compared length of stay, readmission, and costs in patients with ABSSSIs who received oritavancin or vancomycin.

An eVLP cytomegalovirus (CMV) vaccine was found to be safe and immunogenic at very low doses in healthy seronegative adults.

Jason Pogue, PharmD, BCPS-AQID, discusses the need for real-world data to support Ceftolozane/tazobactam and shares the findings of his comparative study on using the regimen to treat MDR/XDR Pseudomonas aeruginosa.

Taking a closer look at the infectious disease risks posed by transplantation and what the future might have in store as the scope of transplantation expands.

Keith Kaye, MD, presented the analysis of the RESTORE-IMI 1 phase 3 trial which evaluated imipenem/cilastatin/relebactam versus imipenem/cilastatin plus colistin.

Three new trials, published in CID, highlight potential for intravaginal rings.

Melvin Weinstein, MD, discusses the current and emerging technologies for the laboratory diagnosis of bloodstream infections.

Following a significant spike in cases of cyclosporiasis, the CDC is investigating whether changes in diagnostic testing may be partially responsible for the rise in recent case counts.

Sarah Kemble, MD discusses trends identified from 33 point prevalence surveys that were performed across the Chicago area to identify colonization of Candida auris.

The CDC and USDA-FSIS are investigating an outbreak of Listeria monocytogenes infections linked to ready-to-eat deli ham products.

Neotrope announced the C diff Foundation as a recipient of the JL Simmons NonProfit PR Grant.

Long-term safety and efficacy data from the pivotal phase 3 EMERALD trial were presented at ID Week 2018.

Investigators from the University of Colorado Boulder have developed a strategy to fight antibiotic-resistant E coli using genetic disruption.

Roy Chemaly, MD, MPH discusses the findings of the phase 2 trial evaluating DAS181 for the treatment of parainfluenza virus lower respiratory tract infections in immunocompromised patients.

The stage may finally be set for the phage therapy era for recalcitrant bacterial infections.

A new report on influenza vaccination rates among US health care workers finds that employer requirements help keep vaccination rates of health care workers higher than that of the general public.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, shares takeaways from her presentation on combination therapy for gram-negative agents at the 2018 SIDP Annual Meeting.

Efforts such as improved indication documentation and antimicrobial stewardship involvement may improve patient outcomes in some patients who are on outpatient parenteral antimicrobial therapy (OPAT) for ease of administration (EOA) that are readmitted to the hospital.

New software to facilitate prior authorization helped streamline the approval process and increase antimicrobial use tracking at the Hospital of the University of Pennsylvania.

Kenneth Sherman, MD, discusses current trends in the treatment of hepatitis B in immunocompromised patients and highlights research exploring treatment options for patients coinfected with HIV.

Letermovir found to prevent clinically significant CMV infection in HCT patients with CMV DNA when compared to placebo in recent phase 3 trial.

A retrospective study evaluates ceftolozane/tazobactam in a large database of US hospitals to determine real-world patterns and outcomes associated with the treatment.

The combination of daptomycin plus fosfomycin was more effective than daptomycin alone for treating patients with MRSA bacteremia.

Results indicate patients who received single-dose oritavancin were significantly less likely to be hospitalized, compared to those who received multidose vancomycin.

We’ve rounded up a list of important US Food and Drug Administration (FDA) and US Department of Agriculture (USDA) recalls from this past week.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The recombinant 9-valent human papillomavirus (HPV) vaccine, Gardasil 9 is now approved in adults 27 to 45 years of age.